Clinical Trial Update: An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas [Phase 2]

View source ↗

Summary

An open-label Phase 2 trial evaluating nanatinostat plus valganciclovir in EBV-positive relapsed/refractory lymphomas has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-associated Lymphoproliferative Disorder
• Epstein-barr Virus-positive Diffuse Large B-cell Lymphoma Not Otherwise Specified
• Epstein-barr Virus-related Hodgkin Lymphoma
• Epstein-barr Virus-related Lymphoproliferative Disease
• Epstein-barr Virus-related Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma Not Otherwise Specified
• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Nanatinostat (nanatinostat)
• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Viracta Therapeutics, Inc. | Conditions: Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS | Phase 2 | Status: TERMINATED | Results posted: 2025-07-28